186 related articles for article (PubMed ID: 22987142)
21. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab.
Guiard E; Karras A; Plaisier E; Duong Van Huyen JP; Fakhouri F; Rougier JP; Noel LH; Callard P; Delahousse M; Ronco P
Clin J Am Soc Nephrol; 2011 Jul; 6(7):1609-16. PubMed ID: 21700823
[TBL] [Abstract][Full Text] [Related]
22. Urine high and low molecular weight proteins one-year post-kidney transplant: relationship to histology and graft survival.
Amer H; Lieske JC; Rule AD; Kremers WK; Larson TS; Franco Palacios CR; Stegall MD; Cosio FG
Am J Transplant; 2013 Mar; 13(3):676-84. PubMed ID: 23414180
[TBL] [Abstract][Full Text] [Related]
23. A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up.
Zhou XJ; Zhou FD; Wang SX; Zhao MH
Medicine (Baltimore); 2018 Jun; 97(25):e11184. PubMed ID: 29924035
[TBL] [Abstract][Full Text] [Related]
24. A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome.
Bazzi C; Petrini C; Rizza V; Arrigo G; D'Amico G
Kidney Int; 2000 Oct; 58(4):1732-41. PubMed ID: 11012907
[TBL] [Abstract][Full Text] [Related]
25. Rituximab treatment of idiopathic membranous nephropathy.
Fervenza FC; Cosio FG; Erickson SB; Specks U; Herzenberg AM; Dillon JJ; Leung N; Cohen IM; Wochos DN; Bergstralh E; Hladunewich M; Cattran DC
Kidney Int; 2008 Jan; 73(1):117-25. PubMed ID: 17943078
[TBL] [Abstract][Full Text] [Related]
26. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Willems HL; Wetzels JF
Nephrol Dial Transplant; 2008 Aug; 23(8):2546-51. PubMed ID: 18308774
[TBL] [Abstract][Full Text] [Related]
27. An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis.
Hoxha E; Harendza S; Zahner G; Panzer U; Steinmetz O; Fechner K; Helmchen U; Stahl RA
Nephrol Dial Transplant; 2011 Aug; 26(8):2526-32. PubMed ID: 21633097
[TBL] [Abstract][Full Text] [Related]
28. Rituximab in idiopathic membranous nephropathy: a one-year prospective study.
Ruggenenti P; Chiurchiu C; Brusegan V; Abbate M; Perna A; Filippi C; Remuzzi G
J Am Soc Nephrol; 2003 Jul; 14(7):1851-7. PubMed ID: 12819245
[TBL] [Abstract][Full Text] [Related]
29. Fractional excretions of albumin and IgG are the best predictors of progression in primary glomerulonephritis.
McQuarrie EP; Shakerdi L; Jardine AG; Fox JG; Mackinnon B
Nephrol Dial Transplant; 2011 May; 26(5):1563-9. PubMed ID: 20921302
[TBL] [Abstract][Full Text] [Related]
30. [Long-term efficacy of low-dose rituximab treatment in patients with primary membranous nephropathy].
Qi Y; Jia JY; Gu QH; Zheng ZF; Li LN; Li D; Jia ZH; Xue Y; Yan TK
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(40):3201-3206. PubMed ID: 36319174
[No Abstract] [Full Text] [Related]
31. [Membranous nephropathy secondary to rheumatoid arthritis occurring during anti-TNFalpha therapy and responsive to second-line treatment with rituximab].
Giordano A; Cencioni L; Salvo DP; Berrettini M
G Ital Nefrol; 2011; 28(2):214-8. PubMed ID: 21488037
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study.
Cravedi P; Sghirlanzoni MC; Marasà M; Salerno A; Remuzzi G; Ruggenenti P
Am J Nephrol; 2011; 33(5):461-8. PubMed ID: 21508634
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.
Fenoglio R; Baldovino S; Sciascia S; De Simone E; Del Vecchio G; Ferro M; Quattrocchio G; Naretto C; Roccatello D
J Nephrol; 2021 Apr; 34(2):565-571. PubMed ID: 32594370
[TBL] [Abstract][Full Text] [Related]
34. Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis.
Huang L; Dong QR; Zhao YJ; Hu GC
Int Urol Nephrol; 2021 Jan; 53(1):111-119. PubMed ID: 32944889
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?].
Busch M; Gerth J; Ott U; Schip A; Haufe CC; Gröne HJ; Wolf G
Med Klin (Munich); 2008 Jul; 103(7):519-24. PubMed ID: 18604487
[TBL] [Abstract][Full Text] [Related]
36. Rituximab therapy for membranous nephropathy: a systematic review.
Bomback AS; Derebail VK; McGregor JG; Kshirsagar AV; Falk RJ; Nachman PH
Clin J Am Soc Nephrol; 2009 Apr; 4(4):734-44. PubMed ID: 19279120
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy.
van den Brand JA; Hofstra JM; Wetzels JF
Clin J Am Soc Nephrol; 2012 Aug; 7(8):1242-8. PubMed ID: 22595828
[TBL] [Abstract][Full Text] [Related]
38. Treatment of Ormond Disease and Idiopathic Membranous Glomerulonephritis by using Rituximab.
Dedinská I; Svetlík D; Adamicova K; Machalekova K; Makovicky P; Jezikova A; Laca L; Miklusica J; Galajda P; Mokan M
Iran J Kidney Dis; 2016 Sep; 10(5):332-335. PubMed ID: 27721233
[TBL] [Abstract][Full Text] [Related]
39. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy.
du Buf-Vereijken PW; Branten AJ; Wetzels JF
Am J Kidney Dis; 2005 Dec; 46(6):1012-29. PubMed ID: 16310567
[TBL] [Abstract][Full Text] [Related]
40. Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies.
El-Zoghby ZM; Grande JP; Fraile MG; Norby SM; Fervenza FC; Cosio FG
Am J Transplant; 2009 Dec; 9(12):2800-7. PubMed ID: 19845581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
